Exenatidacetat CAS:141758-74-9

Beskrivning:

En peptid med 39 aminosyror som ursprungligen isolerades från Gila-monstrets spottkörtlar (Heloderma misstänks), skiljer sig från exendin-3 endast i två positioner nära N-terminalen. Applicering av Exenatid orsakar en ökning av acinär cAMP utan att stimulera amylasfrisättning. Som en inkretinmimetik, Exenatid fungerar som agonist för den glukagonliknande peptiden-1 (GLP-1) receptor. Som GLP-1, though with prolonged activity, Exenatide augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, Exenatide has found use as a medication of diabetes II.

Ansökan:

Exenatide is believed to facilitate glucose control in at least five ways:

1. Exenatide augments pancreas response and more appropriate amount of insulin that helps lower the rise in blood sugar from eating.

2. Exenatide also suppresses pancreatic release of glucagon, which prevents hyperglycemia (high blood sugar levels).

3. Exenatide helps slow down gastric emptying and thus decreases the rate at which meal-derived glucose appears in the bloodstream.

4. Exenatide has a subtle yet prolonged effect to reduce appetite, promote satiety via hypothalamic receptors.

5. Exenatide reduces liver fat content. Fat accumulation in the liver or nonalcoholic fatty liver disease (NAFLD) is strongly related with several metabolic disorders.